As the GP Summit website correctly notes, government program pricing methodologies, calculations, and enforcement actions have changed significantly since the Patient Protection and Affordable Care Act (PPACA) was passed in March 2010. Just consider the complexities and controversy surrounding the new definition of Average Manufacturer Price (AMP)! (See Secret AMP Letter Emerges; FUL Delay Likely.) Even before the Act's passage, the Center for Medicare and Medicaid Services (CMS) was projecting that government funds will be almost half of outpatient retail prescription spending by 2019. See CMS' New Drug Spending Projections for my analysis of the most recent forecast.
Read more from IIR below.
OFFICIAL DESCRIPTION FROM IIR
Government Programs Summit: The Only Event That Convenes CMS, HRSA, OIG, DOD, and VA Representatives To Help Drug Manufacturers Comply With Policy Pricing, And Operational Requirements in a Post Reform Environment.
Download the 2011 GP Summit Brochure Today. (You'll be asked to create an account.)
The risks are increasing, know the rules.
- $4.05 Billion Dollars have been paid by pharmaceutical manufactures in recent drug pricing settlements
- Individuals are being investigated for Medicaid false claims by the DOJ
- Entire companies can face exclusion from Medicaid and 340B
- OPA has begin rule making for 340B Fines and Overcharges
The GP Summit is the one place you will find the answers. We deliver the government officials who will provide the policy answers you are looking for. View the Agenda.
With competition for the market's attention stronger than ever, your company needs to extend its reach to build relationships and connect with prospects. GPS sponsorships offer a variety of ways to raise your company's profile in this market, both pre-event and on-site. There are many sponsorship opportunities and packages available, and we offer multiple levels to accommodate companies of all sizes.
IIR is looking forward to greeting you in Baltimore in March!
No comments:
Post a Comment